D Alastair S Compston
Overview
Explore the profile of D Alastair S Compston including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
2409
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
Coles A, Arnold D, Bass A, Boster A, Compston D, Fernandez O, et al.
Ther Adv Neurol Disord
. 2021 May;
14:1756286420982134.
PMID: 34035833
Background: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 consecutive days 12 months later significantly...
2.
Steingo B, Al Malik Y, Bass A, Berkovich R, Carraro M, Fernandez O, et al.
J Neurol
. 2020 Jun;
267(11):3343-3353.
PMID: 32583052
Background: In the phase 2 CAMMS223 trial (NCT00050778), alemtuzumab significantly improved clinical and MRI outcomes versus subcutaneous interferon beta-1a over 3 years in treatment-naive patients with relapsing-remitting MS. Here, we...
3.
Oh J, Achiron A, Celius E, Chambers C, Derwenskus J, Devonshire V, et al.
Mult Scler Relat Disord
. 2020 Jun;
43:102146.
PMID: 32498033
Background: Relapsing-remitting multiple sclerosis (RRMS) is frequently diagnosed in women of reproductive age. Because the use of disease-modifying therapies (DMTs) early in the disease course is increasing, it is important...
4.
Wray S, Havrdova E, Snydman D, Arnold D, Cohen J, Coles A, et al.
Mult Scler
. 2018 Oct;
25(12):1605-1617.
PMID: 30289355
Background: Reduced MS disease activity with alemtuzumab versus subcutaneous interferon beta-1a (SC IFNB-1a) in core phase 2/3 studies was accompanied by increased incidence of infections that were mainly nonserious and...
5.
Cerqueira J, Compston D, Geraldes R, Rosa M, Schmierer K, Thompson A, et al.
J Neurol Neurosurg Psychiatry
. 2018 Apr;
89(8):844-850.
PMID: 29618493
No abstract available.
6.
Coles A, Cohen J, Fox E, Giovannoni G, Hartung H, Havrdova E, et al.
Neurology
. 2017 Aug;
89(11):1117-1126.
PMID: 28835403
Objective: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. Methods: In the 2-year Comparison of Alemtuzumab and...
7.
Havrdova E, Arnold D, Cohen J, Hartung H, Fox E, Giovannoni G, et al.
Neurology
. 2017 Aug;
89(11):1107-1116.
PMID: 28835401
Objective: To evaluate 5-year efficacy and safety of alemtuzumab in treatment-naive patients with active relapsing-remitting MS (RRMS) (CARE-MS I; NCT00530348). Methods: Alemtuzumab-treated patients received treatment courses at baseline and 12...
8.
Giovannoni G, Cohen J, Coles A, Hartung H, Havrdova E, Selmaj K, et al.
Neurology
. 2016 Oct;
87(19):1985-1992.
PMID: 27733571
Objective: To characterize effects of alemtuzumab treatment on measures of disability improvement in patients with relapsing-remitting multiple sclerosis (RRMS) with inadequate response (≥1 relapse) to prior therapy. Methods: Comparison of...
9.
Arnold D, Fisher E, Brinar V, Cohen J, Coles A, Giovannoni G, et al.
Neurology
. 2016 Sep;
87(14):1464-1472.
PMID: 27590291
Objective: To describe detailed MRI results from 2 head-to-head phase III trials, Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis Study I (CARE-MS I; NCT00530348) and Study II (CARE-MS...
10.
Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N, et al.
J Neurol Neurosurg Psychiatry
. 2014 May;
86(2):208-15.
PMID: 24849515
Objectives: Alemtuzumab is a newly licensed treatment of active relapsing-remitting multiple sclerosis (RRMS) in Europe, which in phase II and III studies demonstrated superior efficacy over β-interferon in reducing disability...